This educational activity will address the recent knowledge acquired in endometrial cancer mainly the indications for adjuvant RT and chemotherapy and the role of concurrent chemoradiation in high risk and locally advanced disease as well as the optimal sequencing approach when both modalities are used. In addition, the interpretation and potential impact of molecular markers will be discussed given the recent publication of the European guidelines which based their recommendations on molecular markers. Last, the interpretation and optimal management of sentinel LN biopsy, isolated tumor cells findings and MELF will be addressed. Recently published prospective trials and ongoing clinical trials will be reviewed.
This session will help to inform the general practitioner regarding updates in the management of cervical cancer.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Determine the indications for systemic therapy and radiation therapy in non-metastatic endometrial cancer.
- Understand the role of molecular markers and their potential impact on adjuvant therapy.
- Interpret the significance and interpretation of sentinel LN biopsy and isolated tumor cells in LN.
- Role of MELF in decision making.
- QOL after concurrent chemoradiation.
- Understanding of the factors associated with local failure after definitive chemo-RT for cervical cancer.
- Understanding of the morbidities after definitive chemo-RT and how to reduce them.
- Understanding indications for post-operative treatment following surgery for earlier staged cervical cancer.
Lara Hathout, MD, is employed by Rutgers Cancer Institute of New Jersey and received compensation from RTOG Foundation.
Mitchell R. Kamrava, MD, MHDS, is employed by Cedars-Sinai Medical Center and received compensation from Alessa, GammaTile and Springer. He also received honorarium for theregenics. He serves in leadership positions for the ABR and ADROP.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.